Amneal Pharmaceuticals
AMRX
129 hedge funds and large institutions have $488M invested in Amneal Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 50 increasing their positions, 32 reducing their positions, and 17 closing their positions.
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
56% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 32
55% more capital invested
Capital invested by funds: $314M → $488M (+$173M)
7% more funds holding
Funds holding: 121 → 129 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.07% less ownership
Funds ownership: 84.51% → 75.43% (-9.1%)
91% less call options, than puts
Call options by funds: $75K | Put options by funds: $850K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.49M |
| 2 |
Millennium Management
New York
|
+$3.38M |
| 3 |
Bank of New York Mellon
New York
|
+$2.74M |
| 4 |
MSL
Mackay Shields LLC
New York
|
+$2.73M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32.7M |
| 2 |
Morgan Stanley
New York
|
-$5.97M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.93M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.29M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.27M |
AMRX Hedge Fund Activity: Q4 2019 in Review
129 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2019, worth a combined $488M — up 55% from $314M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AMRX positions and 17 closed out — a net gain of 10 holders — while 50 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $6.49M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $32.7M sold.
- 129 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2019, up from 121 in Q3 2019.
- Funds reported $488M of Amneal Pharmaceuticals stock for Q4 2019, up 55% quarter-over-quarter.
- 27 funds opened new Amneal Pharmaceuticals positions in Q4 2019 and 17 closed out, a net change of +10 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2019 was BlackRock, an estimated $6.49M added.
- The largest Amneal Pharmaceuticals seller in Q4 2019 was T. Rowe Price Associates, an estimated $32.7M sold.
Based on aggregated 13F filings for Q4 2019.